The USPTO officially received and docketed trademark application TM99192498 for the word mark 'DELKARMI' covering pharmaceutical preparations and products for oncology diseases and disorders. The application was filed on May 19, 2025, under Intent-to-Use basis, with the applicant indicating plans to use the mark in commerce by March 31, 2026.

This filing represents a routine trademark prosecution matter before the USPTO. Third parties who believe this mark may cause confusion with existing marks in Class 005 have a limited window to file an opposition. No immediate compliance actions are required of pharmaceutical manufacturers, though companies with similar oncology pharmaceutical marks should review their portfolios for potential conflict.